Pressemeddelelse

Nightingale Health selected as provider for landmark Italian population study

Nightingale Health Plc | Press Release | July 07, 2025 at 08:00:00 EEST

Nightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF), a pioneer in disease risk detection and preventative health, has been selected as the metabolomics analysis provider for the renowned Moli-sani study, a major population-based research initiative in Italy. This selection reinforces Nightingale Health’s position as a global leader in large-scale metabolomics.

Nightingale Health was selected in accordance with the Italian Public Contracts Code, and the parties will now proceed to finalizing a service agreement. The analysis is expected to be completed by the end of 2025, with a total contract value of approximately EUR 728,000.

The Moli-sani study, led by INM Neuromed, investigates risk factors associated with major chronic diseases. With Nightingale Health’s advanced technology, the study will now examine the impact of nutritional and environmental factors on health. The study also explores biological signatures associated with healthy aging and aims to identify population subgroups with different responses to preventative interventions.

“We are proud to be selected for yet another landmark study that contributes to the prevention of chronic diseases,” says Teemu Suna, Founder and CEO of Nightingale Health. “As the first ’omics technology globally adopted in routine nationwide primary healthcare, our platform offers a straightforward path to clinical application. We believe this collaboration with INM Neuromed will generate impactful insights that bridge medical research and real-world healthcare.”

INM Neuromed is an Italian healthcare and research institute operating as an IRCCS (Scientific Institute for Research, Hospitalization and Healthcare), which means it is recognized by the Italian Ministry of Health as a center of national importance for both clinical care and scientific research. The institute integrates healthcare provided by its clinical departments with research, teaching, and training.

INM Neuromed’s studies, conducted in collaboration with other Italian and international research institutions, represent an important contribution to the ongoing global effort for a greater understanding of the evolution of degenerative diseases, their causes and more accurate prevention strategies. The Moli-sani cohort represent a general population sample, making findings broadly applicable to public health. The metabolomics analysis for the Moli-sani is funded by the European Union, further underlining the study’s scientific and societal relevance.

About Nightingale Health
Nightingale Health has developed the world's most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/